Can a Chemo-Antibody combo beat a tough leukemia?
NCT ID NCT03488225
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding the targeted antibody-drug inotuzumab ozogamicin to a standard chemotherapy regimen (Hyper-CVAD) improves outcomes for adults with B-cell acute lymphoblastic leukemia. The study enrolls people with newly diagnosed or recently remitted disease. Researchers are measuring how long participants remain free of cancer progression or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of chemotherapy drugs (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) plus the antibody-drug conjugate inotuzumab ozogamicin
- What this could lead to
- If successful, this approach could offer a more effective first-line treatment for B-cell acute lymphoblastic leukemia, potentially improving remission rates and long-term survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination therapy carries risks of serious side effects, including infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Personalized chemo dosing may boost leukemia remission in kids
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers